These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38117666)

  • 41. Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.
    Gharbiya M; Cruciani F; Mariotti C; Grandinetti F; Marenco M; Cacace V
    J Ocul Pharmacol Ther; 2015; 31(6):357-62. PubMed ID: 26133059
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Insights From Survival Analyses During 12 Years of Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration.
    Fu DJ; Keenan TD; Faes L; Lim E; Wagner SK; Moraes G; Huemer J; Kern C; Patel PJ; Balaskas K; Sim DA; Bunce C; Stratton I; Keane PA
    JAMA Ophthalmol; 2021 Jan; 139(1):57-67. PubMed ID: 33211064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of ranibizumab, aflibercept, and dexamethasone implant monotherapy in treatment-naive eyes with diabetic macular edema: A 12-month real-life experience.
    Parca O; Cetin EN
    Indian J Ophthalmol; 2024 May; 72(Suppl 3):S453-S458. PubMed ID: 38648453
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
    Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S
    Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.
    Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B
    Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
    Monés J; Biarnés M;
    Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
    Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
    Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term dynamic changes and influencing factors of corneal morphology after multiple intravitreal injections of anti-VEGF drugs.
    Qi Y; Li C; Ye S; Zhang Z; Li S; Zhang L
    Medicine (Baltimore); 2024 Apr; 103(17):e37937. PubMed ID: 38669379
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Topical Dorzolamide-Timolol With Intravitreous Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration.
    Sridhar J; Hsu J; Shahlaee A; Garg SJ; Spirn MJ; Fineman MS; Vander J
    JAMA Ophthalmol; 2016 Apr; 134(4):437-43. PubMed ID: 26914218
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration.
    Eckardt F; Lorger A; Hafner M; Klaas JE; Schworm B; Kreutzer TC; Priglinger SG; Siedlecki J
    Sci Rep; 2024 Apr; 14(1):9600. PubMed ID: 38671028
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Neovascular Age-Related Macular Degeneration (AMD): One-Year Results].
    Pfau M; Fassnacht-Riederle HM; Freiberg FJ; Wons JB; Wirth M; Becker MD; Michels S
    Klin Monbl Augenheilkd; 2016 Aug; 233(8):945-50. PubMed ID: 27123887
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.
    Barthelmes D; Campain A; Nguyen P; Arnold JJ; McAllister IL; Simpson JM; Hunyor AP; Guymer R; Essex RW; Morlet N; Gillies MC;
    Br J Ophthalmol; 2016 Dec; 100(12):1640-1645. PubMed ID: 26994110
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration.
    Spooner K; Hong T; Nair R; Chow NCC; Broadhead GK; Wijeyakumar W; Chang AA
    Acta Ophthalmol; 2019 Aug; 97(5):e706-e712. PubMed ID: 30740921
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab.
    Narayan DS; Muecke J
    Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ROLE OF ADDITIONAL DEXAMETHASONE FOR THE MANAGEMENT OF PERSISTENT OR RECURRENT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDER RANIBIZUMAB TREATMENT.
    Rezar-Dreindl S; Eibenberger K; Buehl W; Georgopoulos M; Weigert G; Krall C; Dunavoelgyi R; Schmidt-Erfurth U; Sacu S
    Retina; 2017 May; 37(5):962-970. PubMed ID: 27575409
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD.
    Thorell MR; Nunes RP; Chen GW; Doshi RR; Dugar J; George MK; Kim BT; Lowrance MD; Modi D; Nahas Z; Gregori G; Yehoshua Z; Feuer W; Rosenfeld PJ
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):526-33. PubMed ID: 25423632
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.
    Muftuoglu IK; Arcinue CA; Tsai FF; Alam M; Gaber R; Camacho N; You Q; Freeman WR
    Am J Ophthalmol; 2016 Jul; 167():1-9. PubMed ID: 27049000
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.
    Razavi S; Kodjikian L; Giocanti-Aurégan A; Dufour I; Souied E
    BMC Ophthalmol; 2021 Feb; 21(1):90. PubMed ID: 33596867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.